Thanks for sharing this post from YMB. One of

Thanks for sharing this post from YMB.

One of the shortcomings of the S/C trial was not including the cytokine labs and other labs used on the EIND patients under Dr. SMJ’s care in NY. NP was asked if the labs were included in the trial and he said they were not, due to cost, which likely would’ve increased costs by a significant amount.

The one part of the post I disagree with is that CYDY has been receiving lab data and reviewing it. This has been discussed here many times. Simple labs such as platelets and bilirubin are ordered and processed at each of the hospitals and recorded in the patient’s chart. In some cases these labs may be drawn daily to track the patient’s clinical progress (that’s a lot of data depending on length of stay and disease profession). There is no reason for the labs to be reported to CYDY before unblinding as that could increase the risk of accidental unblinding due to possible correlation of analysis (that’s a bad thing). Lastly, even if CYDY could view the platelet and bilirubin data, I’m sure there’s an established correlation between increasing platelets/decreasing bilirubin and survival in COVID patients.